Multiple Bispecific Formats
CHO & HEK293 Expression
Dual-Binding Validated
SPR / BLI Characterization
GMP-Grade Available
Service Overview
Engineering Dual Specificity for Next-Generation Therapeutics
Bispecific antibodies represent a rapidly growing class of next-generation biologics, enabling simultaneous engagement of two distinct antigens or epitopes to achieve mechanisms of action impossible with conventional monospecific antibodies — including T-cell redirection, dual checkpoint blockade, dual receptor targeting, and conditional activation. ICDMO's bispecific antibody development service offers a comprehensive portfolio of formats supported by world-class protein engineering, recombinant expression, and biophysical characterization capabilities.
Our experienced scientists guide you from target pair selection and format strategy through construct engineering, expression optimization, purification, and rigorous characterization, accelerating your path from concept to IND-ready material.
8+
Bispecific Formats
95%+
Monomer Purity
IND-Ready
GMP Capability
Bispecific Formats
Supported Bispecific Architectures
We support a wide range of bispecific formats — IgG-like, fragment-based, and custom architectures — tailored to your MOA and CMC requirements.
What We Offer
Bispecific Design & Format Selection
▸Target pair analysis: antigen proximity, receptor stoichiometry, and desired mechanism of action
▸Format recommendation: IgG-like, BiTE, DART, DVD-Ig, CrossMab, or custom based on half-life, valency, and CMC requirements
▸Computational modeling of bispecific architecture and linker optimization
▸Affinity balancing strategy to ensure simultaneous dual engagement without steric clash
▸Immunogenicity in silico assessment of linker and junction sequences
Bispecific Antibody Construction
▸Gene synthesis of bispecific construct (codon-optimized for CHO or HEK293 expression)
▸Vector engineering for co-expression of two heavy chains + two light chains
▸Knobs-into-holes, charge pair, or CrossMab mutations introduced for correct heavy chain pairing
▸Common light chain strategy or separate light chain co-expression with chain pairing confirmation
▸Transient expression screening in HEK293 for rapid format validation before stable line generation
Production & Purification
▸Transient CHO or HEK293 expression: 0.1 mg to 500 mg scale
▸Stable CHO cell line development for GMP-grade manufacturing
▸Protein A capture → low-pH elution → secondary polishing (IEX or HIC)
▸Mispairing removal: Ion exchange chromatography to separate homo- from hetero-dimers
▸SEC-HPLC aggregate removal; final formulation in PBS or custom buffer
Bispecific Characterization
▸SDS-PAGE (reducing and non-reducing) confirming correct MW and chain pairing
▸SEC-HPLC monomer purity (>95% standard); native MS for intact molecular weight
▸Dual-target binding ELISA: simultaneous binding to both antigens confirmed
▸Affinity measurement by SPR (Biacore) or BLI (Octet) for each binding arm independently
▸Functional assay: T-cell killing (for BiTEs), receptor signaling blockade, or dual receptor internalization
▸In vitro stability: forced degradation, freeze-thaw, and thermal stability (DSF) studies
Key Advantages
Multi-Format Expertise
IgG-like, BiTE, DART, DVD-Ig, CrossMab, half-body exchange, and custom formats — all supported under one roof.
Validated Pairing Strategies
Knobs-into-holes, charge pairs, common light chain, and CrossMab strategies ensure correct heavy chain heterodimerization.
Comprehensive Characterization
Intact mass by native MS, dual-target ELISA, SPR/BLI kinetics for each arm, functional T-cell killing or receptor blocking assays.
Rapid Feasibility Turnaround
Transient HEK293 expression at small scale delivers initial bispecific material within 3–4 weeks for format validation.
GMP-Compatible Process
Stable CHO cell line development and cGMP bioreactor manufacturing available for IND-enabling and clinical-stage programs.
One-Stop Therapeutic Pipeline
Seamlessly paired with upstream antibody generation, downstream ADC conjugation, and in vivo efficacy evaluation services.
Development Workflow
1
Target Pair Review & Format Strategy
Submit your two target antigens, desired MOA, and indication. Our antibody engineers assess pairing feasibility, recommend optimal bispecific format, and outline the full development plan.
2
Parental Antibody Sourcing or Development
Use your existing antibodies or engage ICDMO's antibody development service. Variable region sequences are analyzed for compatibility and any required humanization or affinity maturation identified.
3
Bispecific Construct Engineering
Gene synthesis of the complete bispecific construct. Knobs-into-holes or charge-pair mutations introduced. Common light chain or CrossMab design applied as appropriate. Sequence verified before expression.
4
Small-Scale Transient Expression & Screening
Transient transfection in HEK293 or CHO cells at 50–200 mL scale. SDS-PAGE and dual-ELISA screening to confirm bispecific format, pairing efficiency, and dual-binding activity.
5
Scale-Up Production & Purification
Scale-up in bioreactor or spinner flask. Multi-step chromatography purification. Monomer purity confirmed by SEC-HPLC. Mispaired homodimers removed by IEX. Final QC batch record prepared.
6
Comprehensive Characterization & Delivery
Full biophysical and functional characterization: SEC-HPLC, native MS, SPR/BLI binding kinetics for both arms, dual-ELISA, functional cytotoxicity or receptor blockade assay. CoA and data package delivered.
Service Process
1
Strategy Consultation
›
2
Construct Design
›
3
Expression & Screening
›
4
Scale-Up & Purification
›
5
Characterization & Delivery
Specifications & Timeline
Note: Bispecific antibody development timelines depend on target pair difficulty, format complexity, and expression optimization requirements. Contact us for a project-specific feasibility assessment and timeline estimate.
Get a Custom Quote
Bispecific experts respond within 24 hours with a format strategy, feasibility assessment, and proposal.
Contact Us Online ConsultationStandard Deliverables
✓Sequence-verified expression plasmid
✓Purified bispecific antibody
✓SDS-PAGE (reducing & non-reducing)
✓SEC-HPLC monomer purity report
✓Dual-target binding ELISA
✓SPR/BLI binding kinetics (both arms)
✓Certificate of Analysis (CoA)
Why ICDMO?
8+ Bispecific Formats Supported
CHO & HEK293 Expression
In-House SPR / BLI Characterization
GMP Manufacturing Available
One-Stop Therapeutic Pipeline